SEATTLE, July 22, 2021, (MEDGADGET) — Global Ciclesonide Market Analysis
Overview
Ciclesonide is a medication used to treat asthma symptoms such as trouble breathing, chest pains, wheeze, and sneezing in adults and children aged 12 and above. It is a corticosteroid medicine that reduces swelling and inflammation in the airways, making breathing easier. Ciclesonide is available as an aerosol or a nasal spray, and it is commonly inhaled twice a day. It aids in the prevention of asthma attacks, which include shortness of breath, congestion, and coughing.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2291
According to the conclusions of a research released by the Asthma and Allergy Foundation of America (AAFA) in October 2015, polluted air can aggravate asthma symptoms. The same source added that another study of young campers with moderate to severe asthma concluded that greater pollution summer days were 40 percent more likely than days with medium pollution levels to cause acute asthma attacks. Pollution is a prominent cause of asthma in humans, and they are exposed to a variety of pollutants such as vehicle fumes, burning wood, pollen, fumes, and car exhaust, all of which irritate and swell the airways, prompting asthma symptoms.
In 2018, the global ciclesonide market was anticipated to be worth US$ 565.4 million, with a CAGR of 1.9 percent projected for the forecast period (2018–2026).
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2291
Drivers
Ciclesonide is a drug that is commonly used to treat asthma and allergic rhinitis. Allergy rhinitis and asthma are highly prevalent illnesses, and their prevalence is relatively high in nations like the U.S., the U.K, China, and India. As a result, the increasing incidence of allergic rhinitis is likely to fuel growth of the global ciclesonide market during the forecast period. As per the 2018 Global Asthma Report, asthma kills over 1,000 people per day and affects 339 million people throughout the world. Asthma is becoming more common, and those in low- and middle-income nations are the most affected.
As per the National Center for Biotechnology Information (NCBI), the incidence of allergic rhinitis among children and adolescents, as well as young adults, was roughly 15%–25% throughout Asia, Europe, the Americas, and Africa in January 2018.
Ciclesonide is a new kind of inhaled corticosteroid that is used to relieve the symptoms of asthma and COPD. This presents a significant potential for leading market participants to introduce ciclesonide-based products.
Owing to the low presence of market participants, key firms have an opportunity to explore unexplored prospective markets where the incidence of allergic rhinitis and asthma is very high and ciclesonide accessibility is limited. As per the Global Asthma Report issued in 2018, the burden of asthma is significant in several Asian Pacific nations such as China, India, Indonesia, Malaysia, and Thailand; nonetheless, asthma remains underdiagnosed and undertreated. The same source added that many asthma sufferers do not use inhaled corticosteroids since they are either unavailable or prohibitively expensive. As a result, prominent companies may concentrate their efforts on these areas, filling an unmet demand in these high-potential locations and generating significant market income.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/ciclesonide-market-to-surpass-us-6576-million-threshold-by-2026-1188
Restraints
Although, the availability of other therapies and the danger of pneumonia and other respiratory diseases among asthmatic children who take inhaled corticosteroids (ICS) may stifle the global ciclesonide market’s growth.
Ciclesonide is a drug that is used to treat and control allergic rhinitis and asthma. Although, for the treatment of allergic rhinitis and asthma, different medications with a superior treatment regimen are available. Over the forecast period, this is projected to increase competition and impede the adoption of ciclesonide. Veramyst Nasal Spray, manufactured by GlaxoSmithKline Plc., is used to treat seasonal and perennial allergic rhinitis. Merck & Co., Inc.’s NASONEX (mometasone furoate monohydrate) Nasal Spray is used to cure the nasal symptoms of allergic rhinitis.
Furthermore, the expiry of the patent on ciclesonide and the following entry of generic ciclesonide on the market might stifle the drug’s growth in the near future.
With the expiration of branded ciclesonide drugs such as OMNARIS Nasal Spray and ALVESCO, generic producers are likely to join the market. The introduction of generic versions of ciclesonide will enhance competition and limit market revenue growth since generic medicines are less expensive. According to Sepracor Inc.’s annual report, the patents for OMNARIS Nasal Spray and ALVESCO HFA expired in October 2017. As a result, a patent loss might have an impact on market revenue growth.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2291
Regional Analysis
Due to the high incidence of allergic rhinitis and asthma in this region, and the rising number of medication releases, North America is predicted to lead the global ciclesonide market in 2017. Sunovion Pharmaceuticals Inc. gained FDA clearance for its Zetonna nasal spray for the treatment of allergic rhinitis and introduced it in the U.S. Market in 2012. Additionally, as per the American Academy of Allergy, Asthma, and Immunology, 8.3 percent of children in the U.S. had asthma in 2016.
Competitive Landscape
Major companies contributing in the global ciclesonide market are Cipla Limited, AstraZeneca Plc., Apotex Inc., and Sun Pharmaceutical Industries Ltd.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Indication
- Market Snippet, By Dosage Form
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- New Product Approvals & Launches
- Market Dynamics
- Global Ciclesonide Market, By Indication, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Allergy Rhinitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Introduction
- Global Ciclesonide Market, By Dosage Form, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Aerosol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Introduction
- Global Ciclesonide Market, By Region, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2026
- North America
- Market Size and Forecast, By Indication, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Indication, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Indication, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Indication, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Indication, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Indication, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Section
- References
- Research Methodology
- About Us and Sales Contact
Other Exclusive Reports:
Polycythemia Vera Therapeutics Market To Surpass US$ 1,516.5 Million By 2028
Genital Warts Treatment Market To Surpass US$ 2,253.6 Million By 2028
Castrate-Resistant Prostate Cancer Market To Surpass US$ 16.4 Billion By 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837